Suite of Asthma Control and Asthma Impact Surveys
Launched by QualityMetric Incorporated

Founded by the developer of the SF-36^® and other leading generic and disease-specific patient-reported outcome (PRO) surveys, QualityMetric now offers a full suite of asthma impact and asthma control measurement solutions for pharmaceutical enterprises, health plans, disease management companies, hospitals/health systems, employers, government agencies, and academic researchers*. (*Note: All QualityMetric surveys are royalty-free for scholarly research).

There are currently more than 130 therapeutic products in development in the United States to treat asthma and respiratory allergies, but those making it to launch will have a difficult time penetrating the marketplace. Currently available products have good efficacy and safety profiles with high levels of prescriber confidence. Payers are also comfortable with current products and will be wary of new ones that don't address an unmet therapeutic need.

However, prescribers and payers alike recognize the need for products that improve patient compliance with asthma treatment. QualityMetric, with over three decades of experience in the development of precise and scientifically validated generic and disease-specific PRO surveys, offers a complete suite of asthma measurement tools sensitive to both “impact” and “control”. Integrating the patient’s voice in the measurement of their health is widely recognized as an effective compliance strategy and can also be counted on:

In product development and launch phases to:

• Raise public awareness of asthma
• Prove the therapeutic efficacy of a particular product beyond traditional clinical endpoints
• Facilitate timely regulatory approval for new asthma products
• Substantiate product marketing and label claims
• Demonstrate the effectiveness of one asthma product over another with scientifically valid measurement

And in clinical treatment to:

• Identify those in need of treatment
• Measure the burden(impact) of asthma on patients and populations
• Monitor the effectiveness of asthma treatment, comparing data results with standardized norms and benchmarks
• Provide clinically meaningful interpretation of the results

QUALITYMETRIC ASTHMA SURVEYS

Asthma Control Measurement: Evaluates asthma risk and measures treatment effectiveness by screening and monitoring change in asthma control over time. Well-suited to measure the degree of control in a variety of settings ranging from clinical practice to disease management and clinical trials.

Asthma Impact Measurement: Assesses the impact of disease on functional status and well-being to evaluate outcomes in clinical trials, identify patients in need of treatment and/or monitor treatment outcomes in clinical practice.

Adult Asthma

Control 

• Asthma Control Test™

Impact 

• Asthma Impact™ Survey
• DYHNA^® Asthma Impact

Pediatric Asthma

Control 

• Asthma Control Test™(Self-administered from age 12 and over)

Impact 

• Pediatric Asthma Impact Survey™(Care-giver administered)
• DYHNA^® Pediatric Impact(Care-giver administered)

The Best of Both Measurement Worlds: Why Use Generic and Disease-specific PRO Surveys

A QualityMetric generic health survey (SF-36^®, SF-36v2™, SF-12^®, SF-12v2™, and SF-8™ Health Surveys), in combination with a disease-specific measure, provides a more broadly defined picture of a patient’s overall health-related quality of life (HRQoL) and offers the ability to compare data results with general and disease specific population norms. More than 7,000 articles in over 1,100 international journals cite use of the SF™ Generic Health Surveys involving research in 64 diseases and conditions.

The SF-36® and SF-12® Health Surveys are registered trademarks of the Medical Outcomes Trust.
The SF-36v2™, SF12v2™, and SF-8™ Health Surveys are trademarks of QualityMetric Incorporated,
640 George Washington Highway, Lincoln, Rhode Island 02865.

QualityMetric Incorporated

This email has been circulated by BioPortfolio Ltd on behalf of QualityMetric Incorporated. As a registered user of the BioPortfolio web sites, you were selected to receive this message in the genuine belief that it would be of interest to you. Subscriber information: To unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com WITH NO SUBJECT.  The system will automatically remove your email address from the list based on your email address.  If your email has changed please email peter.barfoot@bioportfolio.com with a list of your email address and we will manually unsubscribe for you.  Thank you for your understanding. To subscribe for the BioPortfolio Bulletin in HTML, email: bioportfolio-subscribe-request@peach.ease.lsoft.com Disclaimer: BioPortfolio Limited and its agents used their best efforts in collecting and preparing the information published herein. However, BioPortfolio does not assume, and hereby disclaims, any and all liability for any loss or damage caused by errors, whether such errors resulted from negligence, accident, or other causes. All rights reserved. ©2004 BioPortfolio Limited

BioPortfolio is the essential web resource for scientists, executives, investors, the public and the patient with an interest in who, what, where, when and why biotechnology will impact on our lives. We have created proprietary databases and search engines that will support your business and private interests in the most exiting technology of the 21st Century. BioPortfolio provides 14 Channels: www.bioportfolio.com/